

Anteo Enters 5-year Agreement with Next Generation PoC Company

28 October 2016

- **Ellume integrate Anteo technology into their proprietary quantum dot diagnostic platform**
- **Anteo and Ellume sign a long-term supply arrangement with minimum annual requirements**
- **Validates the value of Anteo's technology in the Point-of-Care (PoC) market segment**

Anteo Diagnostics Limited (ASX: ADO) is pleased to announce that it has entered a long-term supply arrangement with Ellume Pty Ltd. based in Brisbane, Australia.

Established in 2010, Ellume has developed a pioneering quantum dot detection system combining nano-technology and unique opto-electronics resulting in a next generation immunoassay platform. Ellume has used this technology to create products distinguished by their technical performance, simplicity of design, ease of use, rapid time to result and connectivity. Anteo worked with Ellume in the early stages of quantum dot enablement to deliver a customised formulation of Anteo's unique metal-ion based nanometre-thin chemistry.

Anteo COO Ms Tamara Mills said, "We are pleased to see that Anteo's technology has delivered a strong technical proposition and commercial solution for Ellume. We believe Anteo's platform technology is well placed to enable the next wave of breakthrough PoC technologies, particularly as the limitations of the traditional biomolecule coupling methods struggle to meet the demands associated with nano-technology."

Ellume Managing Director, Dr Sean Parsons, said, "Anteo technology forms an important layer in our proprietary quantum-dot based technology and we are pleased to have entered into this long-term agreement."

The undisclosed commercial arrangement shall see Ellume utilise Anteo's proprietary technology across its suite of pipeline products. The first to be launched influenza product will be released to the professional market in 2017. Other pipeline products include Respiratory Syncytial Virus, Group A Streptococcus and Chlamydia.

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the

gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

Through its wholly owned subsidiary, DIAsource Immunoassays SA, Anteo Group manufactures and distributes a complete catalogue of ELISA and RIA products for clinical diagnostics via established distribution channels in 75 countries across the world, including antibodies and laboratory automation instrumentation.

For more information, please visit www.anteodx.com

About Ellume

Ellume commercialises innovative PoC and consumer-use diagnostics which combine ultra-sensitive detection with clinical connectivity. Ellume has developed techniques to create a novel class of nanoparticle based on quantum dots which is used as an ultra-bright fluorescent reporter in Ellume products. These quantum dot nanoparticles, when bound with detector antibodies and coupled with a single-use fluorescent assay reader, enables substantial improvements in performance when compared to existing systems.

More information on Ellume can be found at www.ellume.com.au